REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 202 filers reported holding REATA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 1.43 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $666,207 | +113200.5% | 6,534 | +0.9% | 0.00% | 0.0% |
| Q1 2023 | $588 | +140.0% | 6,474 | 0.0% | 0.00% | +200.0% |
| Q4 2022 | $245 | -99.8% | 6,474 | +17.2% | 0.00% | 0.0% |
| Q3 2022 | $138,000 | -27.7% | 5,524 | -12.2% | 0.00% | 0.0% |
| Q2 2022 | $191,000 | -4.5% | 6,292 | +2.7% | 0.00% | 0.0% |
| Q1 2022 | $200,000 | +525.0% | 6,124 | +389.9% | 0.00% | – |
| Q4 2021 | $32,000 | -90.7% | 1,250 | -63.7% | 0.00% | -100.0% |
| Q3 2021 | $345,000 | -44.6% | 3,439 | -22.0% | 0.00% | -50.0% |
| Q2 2021 | $623,000 | +268.6% | 4,408 | +159.3% | 0.00% | +300.0% |
| Q1 2021 | $169,000 | -19.5% | 1,700 | 0.0% | 0.00% | -50.0% |
| Q4 2020 | $210,000 | +24.3% | 1,700 | -2.5% | 0.00% | 0.0% |
| Q3 2020 | $169,000 | +4125.0% | 1,743 | +6872.0% | 0.00% | – |
| Q2 2020 | $4,000 | -33.3% | 25 | -39.0% | 0.00% | – |
| Q1 2020 | $6,000 | -40.0% | 41 | -18.0% | 0.00% | – |
| Q4 2019 | $10,000 | +150.0% | 50 | 0.0% | 0.00% | – |
| Q3 2019 | $4,000 | – | 50 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |